@FYang_EP Gold handled needle drivers are sturdier because they are made from tungsten carbide. @rbarbosa91 has great tweetorials on surgical instrument history and use. Super helpful for those of us that use them but never did general surgery training.
@PierreEliasMD@JACCJournals Fantastic study. You all went above and beyond with not only developing an impressive model, but also sharing your code and doing saliency mapping to provide some insight into what ValveNet actually looks at! Congratulations and thank you for sharing.
@HeartRhythmNP@DukeCardiology Maybe more to it than just the burden. ABC-VT score accounts for morphology and other features to predict which PVCs lead to cardiomyopathy. https://t.co/Z1BUeyMhMo
@HeartRhythmNP Haha, I took that same picture! I thought it was a good summary of the current evidence and I liked the patient/treatment matrix for thinking about where the data is.
Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation, by @derek_c1, @JonPicciniSr, and colleagues
https://t.co/gqLvfltBje
Meta-analysis of RCTs finds that catheter ablation for atrial fibrillation reduces mortality, hospitalizations, and increases freedom from arrhythmia vs medical therapy: https://t.co/SUyHHsFgOB. @JCardioEP#EPeeps
Is There a Mortality Benefit of Atrial Fibrillation Ablation? https://t.co/wqi9LVCLuf. Check out out editorial on this meta-analysis of RCTs and it’s implications for future trial design and patient-tailored care. @DukeCardFellows@DukeHeartCenter#EPeeps
Among patients with LBBB undergoing CRT, electrical and mechanical dyssynchrony were both required for the most favorable reverse remodeling and event free survival! @ZakLoringMD@DanFriedmanMD#AHAJournals https://t.co/uPJzTatIR1
@JonPicciniSr@ba_steinberg@DanMarkMD@TJaredBunch@derek_c1 Really interesting paper, great work @ba_steinberg. Changes the way I think about AF and makes me curious as to what mechanisms change during the transition from rare to persistent and the implications for targeted therapies.